Thomas Meier

Thomas Meier was appointed CEO of Santhera, effective October 1, 2011, after hav- ing served seven years as Chief Scientific Officer (CSO) for the Company. Mr Meier was the founder and CEO of MyoContract, a Basel-based research company fo- cused on orphan neuromuscular diseases, which he merged in 2004 with Graffin- ity of Heidelberg, Germany, to form today’s Santhera. In 1999, Mr Meier became an independent research group leader and lecturer in the Department of Phar- macology and Neurobiology at the Univer sity of Basel, Switzerland, where he es- tablished MyoContract as first start-up of the Biozentrum. Mr Meier received his PhD in biology from the University of Basel, Switzerland, in 1992 and subse- quently joined the University of Colorado Health Sciences Center, US. He has a distinguished scientific track record in the field of neuromuscular research. Be- fore joining the industry, Mr Meier was awarded the International Research Fel- lowship Award from the US National In stitutes of Health and a long-term fellow- ship from the Human Frontier Science Foundation. In 2007, he received the Bio- Valley Basel Award for his outstanding contributions to the life sciences in the area.

Thomas Meier is the Co-Founder, Board Member & Chief Executive Officer at Santhera Pharmaceuticals. With a background in Biotechnology, Thomas Meier has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.